TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04435847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HST 001
Description: Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of active treatment (HST 001).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline
Description: Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of placebo control (Phosphate Buffered Saline).
Study: NCT04374487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: 200 ml of ABO compatible plasma transfusion will be done to the subject randomized for the test arm therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care Therapy
Description: Subjects randomized to control group will be on standard care treatment according to Institutional Protocols.
Study: NCT00924547

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexanoic Acid Supplement
Description: The active treatment will consist of Martek's chewable DHA capsules containing 200mg in each capsule. The treatment will be provided as approximately 25mg/kg/day and 35mg/kg/day.~These dosages will be divided BID-TID and will be given for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to active treatment.
Study: NCT01619891

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: 100mcg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 100mcg per day
Study: NCT00169806

Intervention type: OTHER
Group type: OTHER
Intervention: videotape for mapping of renal anatomy and papillary biopsy
Description: Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
Study: NCT03184870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Specified dose on specified days
Study: NCT02701556

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete MPS
Description: a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NNR06
Description: an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
Study: NCT02765880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Connectivity between the areas related to information processing over time and the areas activated during the rest activity. We will verify whether the activation anomalies observed during time tasks predict anomalies in spontaneous activity dynamics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Connectivity between the areas related to information processing over time and the areas activated during the rest activity. We will verify whether the activation anomalies observed during time tasks predict anomalies in spontaneous activity dynamics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Connectivity between the areas related to information processing over time and the areas activated during the rest activity. We will verify whether the activation anomalies observed during time tasks predict anomalies in spontaneous activity dynamics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: link between EEG response anomalies related to information processing over time and response anomalies recorded during rest activity. We will check whether anomalies in EEG oscillatory responses during time tasks predict anomalies during the rest task.
Study: NCT01381588

Intervention type: OTHER
Intervention: Fracture evaluation
Description: DEXA(Dual-energy X-ray absorptiometry), X-ray
Study: NCT02765880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: link between EEG response anomalies related to information processing over time and response anomalies recorded during rest activity. We will check whether anomalies in EEG oscillatory responses during time tasks predict anomalies during the rest task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: link between EEG response anomalies related to information processing over time and response anomalies recorded during rest activity. We will check whether anomalies in EEG oscillatory responses during time tasks predict anomalies during the rest task.
Study: NCT04269642

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PT320 2.0mg Placebo
Description: PT320 2.0mg Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT320 2.0 mg
Description: Exenatide slowly released formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT320 2.5 mg
Description: Exenatide slowly released formulation
Study: NCT02968992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhLactoferrin
Description: Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible participant will be provided with placebo in capsules of 250 mg along with detailed instructions for taking the placebo. Participants will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
Study: NCT05657860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release
Description: Initial dose for all participants will be 1mg per day. If the medication is well tolerated, the dose can be raised to 2 mg until day 28 and increased to 3 mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed., the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8 timepoint, the study will be unblinded.and subjects will continue treatment for 8 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered concurrently with GXR during trials.
Study: NCT03184870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Specified dose on specified days
Study: NCT03600805

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab SAR153191
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab SAR153191
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab matching placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab matching placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: tablets or capsules Route of administration: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: tablets or capsules Route of administration: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form: tablets or capsules Route of administration: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form: tablets or capsules Route of administration: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone matching placebo
Description: Pharmaceutical form: capsules Route of administration: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone matching placebo
Description: Pharmaceutical form: capsules Route of administration: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone matching placebo
Description: Pharmaceutical form: capsules Route of administration: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone matching placebo
Description: Pharmaceutical form: capsules Route of administration: oral administration
Study: NCT04195230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-tasking Training
Description: Participants will undergo training protocol where they will have, concomitantly, to cook different meals and set the table under different instructions, rules and difficulty level.
Study: NCT04039334

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy
Description: Conventional chest physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), teaching of respiratory control, relaxing and coughing techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Chest Physiotherapy
Description: Conventional chest physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), teaching of respiratory control, relaxing and coughing techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Dance Based Exercise Training
Description: Creative dance based exercise training will be given under the supervision of a physiotherapist who takes creative dance instructor training 2 days and 60 minutes per week.
Study: NCT04741893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP
Description: Use of Endoluminal Functional Lumen Imaging Probe to assess anal canal function

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP
Description: Use of Endoluminal Functional Lumen Imaging Probe to assess anal canal function
Study: NCT00685607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loperamide-simethicone
Description: Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: Four placebo caplets matching the caplets in Arm 1, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
Study: NCT03702322

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Voice therapy: respiratory
Description: Abdominal voice onset

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Voice therapy: glottal closure
Description: Pulling/pushing task

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Voice therapy: loud
Description: Assertive task

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Voice therapy: Semiocclusion
Description: Semi-occluded vocal tract
Study: NCT03129763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60mmHg capsule pressure expansion
Description: With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 60mmHg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 70mmHg capsule pressure expansion
Description: With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 70mmHg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 80mmHg capsule pressure expansion
Description: With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 80mmHg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 90mmHg capsule pressure expansion
Description: With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 90mmHg.
Study: NCT03184870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Specified dose on specified days
Study: NCT03222271

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation to NIV
Description: Weaning using NIV immediately after extubation with the mentioned parameters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extubation to NIV
Description: Weaning using NIV immediately after extubation with the mentioned parameters
Study: NCT02332252

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Skin incision performed with a scalpel during cesarean section.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocautery
Description: Skin incision performed with an electrocautery during cesarean section.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin incision
Study: NCT01106638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free
Description: An eight session, group therapy intervention targeting smokers living with HIV/AIDS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Advice to quit, smoking cessation brochure, and offer of nicotine patches
Study: NCT02923271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellControl
Description: Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellControl
Description: Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.
Study: NCT01519843

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation tDCS
Description: tdcs (ELDITH, Neuroconn, Ilmenau, Germany)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation tDCS
Description: tdcs (ELDITH, Neuroconn, Ilmenau, Germany)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation TMS
Description: TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
Study: NCT03597555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate Oral Solution 500 MG/ML
Description: First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
Study: NCT01769443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
Study: NCT01584388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
Study: NCT00610948

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT00876343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole (Fixed dose)
Description: administered orally once daily, 3 mg daily, 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole (Titrated dose)
Description: administered orally once daily, 3 to 15 mg daily, 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally once daily, 6 weeks
Study: NCT03132272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunoadsorption with Globaffin
Description: Immunoadsorption for treatment of persons with Alzheimer Dementia
Study: NCT02428647

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNP
Description: MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: preventive zinc supplement
Description: 7 mg zinc daily as dispersible tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic zinc supplement
Description: 20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: preventive placebo supplement
Description: dispersible daily placebo tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic placebo supplement
Description: dispersible placebo tablet for 10 days during diarrhea episodes

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic placebo supplement
Description: dispersible placebo tablet for 10 days during diarrhea episodes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic placebo supplement
Description: dispersible placebo tablet for 10 days during diarrhea episodes

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo powder
Description: placebo powder
Study: NCT03941821

Intervention type: DRUG
Intervention: Glecaprevir/Pibrentasvir
Description: Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment
Study: NCT02147080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UV4me
Description: Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Cancer Foundation website
Description: Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.
Study: NCT01053468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Resource Kit
Description: The Intervention group (INT) will receive a Physical Activity Resource Kit which includes a step pedometer, a breast cancer-specific Physical Activity Guidebook (Exercise for health), a step pedometer resource (Step into survivorship), and a physical activity and step journal to record their daily step totals and daily physical activities.~Participants will be instructed to wear their pedometer for the entire duration of the study (i.e., chemotherapy duration).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Materials
Description: Participants in this usual care group will receive a generic physical activity leaflet from the Canadian Public Health Agency